Wordt geladen...
Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
The prognosis of patients with unresectable or metastatic urothelial carcinoma (UC) is poor. Platinum-based chemotherapy has been the standard first-line treatment in these patients for the past decade; however, the 5-year overall survival (OS) rate is only 13–22%. Recent advances in cancer immunolo...
Bewaard in:
| Gepubliceerd in: | Cancer Manag Res |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6526676/ https://ncbi.nlm.nih.gov/pubmed/31191013 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S167708 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|